Clinical Trials Logo

Asplenia clinical trials

View clinical trials related to Asplenia.

Filter by:
  • None
  • Page 1

NCT ID: NCT04199403 Recruiting - Asplenia Clinical Trials

Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients

SPLEEN
Start date: January 9, 2020
Phase:
Study type: Observational [Patient Registry]

Spleen could have been surgically removed for trauma, cancer, auto-immune disease, or to perform a diagnosis. Spleen could be non-functional due to radiotherapy or splenic artery embolism. These patients are at risks of infectious diseases due to encapsulated bacteria, cancer, and thromboembolism disease. The purpose of this study is to assess complications occurring in French patients without spleen and to implement new diagnostic tools for follow-up.

NCT ID: NCT02232191 Recruiting - Asplenia Clinical Trials

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Start date: December 2014
Phase: Phase 2
Study type: Interventional

Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.

NCT ID: NCT01846923 Active, not recruiting - ß-thalassemia Major Clinical Trials

B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals

Start date: October 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the 23-valent polysaccharide pneumococcal vaccine influence the cellular immune response to PCV13 in this group.